APLS — курсы расширенных реанимационных мероприятий в педиатрии, спонсируемые Американской академией педиатрии и Американской коллегией врачей неотложной помощи (Advanced Pediatric Life Support)
AVPU — шкала для оценки уровня сознания («в ясном сознании»; «реакция на вербальные раздражители»; «реакция на боль»; «без сознания») (alert, verbal, pain, unresponsive)
CADASIL — церебральная аутосомно-доминантная артериопатия с подкорковыми инфарктами и лейкоэнцефалопатией (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy)
DSM — Диагностическое и статистическое руководство по психическим расстройствам (Diagnostic and Statistical Manual of Mental Disorders)
EAST syndrome — эпилепсия, атаксия, сенсоневральная тугоухость и тубулопатия (epilepsy, ataxia, sensorineural hearing loss, and tubulopath)
EBM — доказательная медицина (evidance based medicine)
EPCAM — молекула адгезии эпителиальных клеток (epithelial cell adhesion molecule)
ESC — Европейское общество кардиологии (European Society of Cardiology)
EXIT — лечение плода вне матки во время родов (ех utero intrapartum treatment)
FcRs — Fc-рецепторы — белок, расположенный на поверхности нескольких видов клеток иммунной системы (естественных киллеров, макрофагов, нейтрофилов и тучных клеток) FDA — Комитет по контролю за лекарственными веществами и пищевыми добавками, США (Food and Drug Administration)
MELAS — митохондриальная энцефалопатия, лактоацидоз и инсультоподобные эпизоды (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes)
MELD — модель для оценки терминальной стадии заболеваний печени, предназначена для оценки относительной тяжести заболевания и прогноза жизни у пациентов с терминальной стадией печеночной недостаточности (ожидающих трансплантации печени) (model for end-stage liver disease)
MERRF — миоклоническая эпилепсия с рваными красными волокнами (myoclonic epilepsy with ragged red fibers)
MHC — главный комплекс гистосовместимости (major histocompatibility complex)
Mr — кажущаяся молекулярная масса
MRP — белок с множественной лекарственной устойчивостью (multidrug-resistant protein)
mTOR — мишень рапамицина у млекопитающих (mammalian target of rapamycin)
NB! — важно, обратить внимание (nota bene)
NICE — Национальный институт здоровья и клинического совершенствования (качества медицинской помощи) Великобритании (National Institute for Health and Clinical Excellence)
NK — естественные клетки-киллеры (natural killer) NMDA — И-метил-В-аспартат (N-methyl-D-aspartate)
NNT — число больных, которых необходимо пролечить, чтобы достичь какого-то указанного эффекта (number need to treatment)
OR — отношение шансов (odds ratio)
paCO2 — парциальное давление углекислого газа в артериальной крови
PALS — курсы расширенных реанимационных мероприятий в педиатрии (Pediatric Advanced Life Support)
PANDAS — аутоиммунное нейропсихиатрическое расстройство в детском возрасте, ассоциированное со стрептококковой инфекцией (pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection)
PANS — острый нейропсихиатрический синдром в детском возрасте (pediatric acute-onset neuropsychiatric syndrome)
paO2 — парциальное давление кислорода в артериальной крови
PAS — фуксинсернистая кислота, реактив Шиффа (periodic acid-Shiff)
PC — после еды (при назначениях) (post cibum) рСО2 — парциальное давление углекислого газа
PCSK-9 — пропротеиновая конвертаза субтилизинкексинового типа 9 (proprotein convertase subtilisin/kexin type 9)
PFAPA — периодическая лихорадка с афтозным стоматитом, фарингитом и лимфаденитом (periodic fevers with aphthous stomatitis, pharyngitis and adenitis)
PIM — показатель летального исхода у детей (pediatric index of mortality)
piO2 — парциальное давление кислорода во вдыхаемом воздухе
рО2 — парциальное давление кислорода
POLG — субъединица ДНК-полимеразы γ
PRISA II — оценка риска госпитализации у детей II (pediatric risk of admission)
PRISM — риск летального исхода у детей (pediatric risk of mortality)
PRN — при (по) необходимости (pro re nata — при возникновении обстоятельств)
PRSS — ген сериновой протеазы
PS — примечание (post scriptum)
PUVA-терапия — псорален-ультрафиолет А-терапия (psoralen and ultraviolet А)
Q#H — каждые # часов (при назначениях) (quaque... hora)
QAM — каждое утро (при назначениях) (quaque ante meridiem)
QPM — каждый вечер (при назначениях) (quaque post meridiem)
RAG — ген, активирующий рекомбиназу
RePEAT — пересмотренный инструмент для оценки педиатрической неотложной медицинской помощи (Revised Pediatric Emergency Assessment Tool)
RF — ревматоидный фактор
Rh — резус(-фактор)
Rh«-» — резус-отрицательн(ый)
Rh«+» — резус-положительн(ый)
ROHHAD — быстро развивающееся ожирение с дисфункцией гипоталамуса, гиповентиляцией и спонтанной дисрегуляцией (rapid-onset obesity with hypothalamic dysfunction, hypoventilation and autonomic dysregulation)
αDG-RD — дистрофии, связанные с α-дистрогликанами (alpha dystroglycan-related dystrophies)
β-ХГЧ — β-субъединица хорионического гонадотропина человека
В ходе подготовки статей по аллергологии и иммунологии в терапии для пользователей сайта МедУнивер использованы труды следующих авторов:
AalberseR.C., Platts-Mills Т.А. How do we avoid developing allergy: modifications of the TH2 response from a В-cell perspective. J. Allergy Clin. Immunol. 2004; 113(5): 983—986.
Almqvist C., Wickman M., Perfetti L., Berglind N., Renstrom A., Hedren M. et al. Worsening of asthma in children allergic to cats, after indirect exposure to cat at school. Am. J. Respir. Crit. Care Med. 2001; 163(3 Pt 1): 694-698.
Arruda L.K., Mann B.J., Chapman M.D. Selective expression of a major allergen and cyto-toxin, Asp f I, in Aspergillus fumigatus.
Implications for the immunopathogenesis of Aspergillus-related diseases. J Immunol 1992; 149(10): 3354-3359.
Blackley C.H. Experimental Researches on the Causes and Nature of Catarrhusaestivus. Balliere, London, 1873.
Braback L., Hjern A., Rasmussen E Trends in asthma, allergic rhinitis and eczema among Swedish conscripts from farming and non-farming environments. A nationwide study over three decades. Clin. Exp. Allergy 2004; 34(1): 38—43.
Chen Y., Dales R., Jiang Y. The association between obesity and asthma is stronger in non-allergic than allergic adults. Chest 2006; 130(3): 890—895.
Clayton E, Fang J.C., Gleich GJ., Lucendo A.J., Olalla J.M., Vinson L.A. et al. Eosinophilic Esophagitis in Adults is associated with IgG4 and not mediated by IgE. Gastroenterology 2014; 147(3): 602-609.
Commins S.P., Kelly L.A., Ronmark Е., James H.R., Pochan S.L., Peters E.J. etal. The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-a-l,3-galactose. JACI 2011; 127(5): 1286—1293.
Commins S.P. et al. Galactose-alpha- 1,3-galactose-speciflc IgE is associated with anaphylaxis but not asthma. Am. J. Respir. Crit. Care Med. 2012; 185(7): 723—730.
Cottrell L., Neal W.A., Ice C., Perez M.K., Piedmonte G. Metabolic abnormalities in children with asthma. Am. J. Respir. Crit. Care Med. 2011; 183(4): 441—448.
Crater D.D., Heise S., Perzanowski M., Herbert R., Morse C.G., Hulsey T.C. et al. Asthma hospitalization trends in Charleston, South Carolina, 1956 to 1997: twenty-fold increase among black children during a 30-year period. Pediatrics 2001; 108(6): E97.
De Blay F., Chapman M.D., Platts-Mills T.A. Airborne cat allergen (Fel d I). Environmental control with the cat in situ. Am. Rev. Respir. Dis. 1991; 143(6): 1334—1339.
Downs S.H., Marks G.B., Sporik R., Belosouva E.G., Car N.G., Peat J.K. Continued increase in the prevalence of asthma and atopy. Arch. Dis. Child 2001; 84(1): 20—23.
Du Toit G., Katz Y., Sasieni P., Mesher D., Maleki S.J., Fisher H.R. et al. Early consumption of peanuts in infancy is associated with a low prevalence of peanut allergy. J. Allergy Clin. Immunol. 2008; 122(5): 984-991.
Du Toit G., Roberts G., Sayre P.H., Bahnson H.T., Radulovic S., Santos A.F. et al. Randomized trial of peanut consumption in infants at risk for peanut allergy. N. Engl. J. Med. 2015; 372(9): 803-813.
Eder W., Ege M.J., von Mutius E. The asthma epidemic. N. Engl. J. Med. 2006; 355(21): 2226-2235.
Ehnert B., Lau-Schadendorf S., Weber A., Buettner P., Schou C., Wahn U. et al. Reducing domestic exposure to dust mite allergen reduces bronchial hyperractivity in sensitive children with asthma. J. All Clin. Immunol. 1992; 90(1): 135—138.
Erwin E.A. et al. Cat and dust mite sensitivity and tolerance in relation to wheezing among children raised with high exposure to both allergens. J. Allergy Clin. Immunol. 2005; 115(1): 74-79.
Erwin E.A., Ronmark E., Wickens K., Perzanowski M.S., Barry D., Lundback B. et al. Contribution of dust mite and cat specific IgE to total IgE: relevance to asthma prevalence. J. Allergy Clin. Immunol. 2007; 119(2): 359—365.
Esch R.E., Bush R.K. Chapter 32: Aerobiology of Outdoor Allergens. Middleton’s Allergy Principals and Practice, 2009. Seventh Edition: 509—538.
Fredberg J.J. Airway smooth muscle in asthma: flirting with disaster. Eur. Respir. J. 1998; 12(6): 1252-1256.
Gilliland F.D., Berhand K., Islam T., McConnell R., Gauderman W.J., Gilliland S.S. et al. Obesity and the risk of newly diagnosed asthma in school-age children. Am. J. Epidemiol. 2003; 158(5): 406-415.
Goran M.I., Treuth M.S. Energy expenditure, physical activity, and obesity in children. Pediatr. Clin. North Am. 2001; 48(4): 931—953.
Gortmaker S.L., Must A., Sobol A.M., Peterson K., Colditz G.A., Dietz W.H. et al. Television viewing as a causse of increasing obesity among children in the United States. Arch. Pediatr. Adolesc. Med. 1996; 150: 356—362.
Grant E.N., Lyttle C.S., Weiss K.B. The relation of socioeconomic factors and racial/ ethnic differences in US asthma mortality. Am. J. Public Health 2000; 90(12): 1923— 1925.
Greer F.R., Sicherer S.H., Burks A.W. Effects of early nutritional interventions on the development of atopic disease in infants and children: the role of maternal dietary restriction, breastfeeding, timing of introduction of complementary foods, and hydrolyzed formulas. Pediatrics 2008; 121(1): 183-191.
Hark W.T., Thompson W.M., McLaughlin Т.Е., Wheatley L.M., Platts-MillsT.A.E. Spontaneous sigh rates during sedentary activity: watching television vs reading. Ann. Allergy Asthma Immunol. 2005; 94(2): 247—250.
Hodson T., Custovic A., Simpson A., Chapman M., Woodcock A., Green R. Washing the dog reduces dog allergen levels, but the dog needs to be washed twice a week. J. Allergy Clin. Immunol. 1999; 103: 581-585.
Kerrebijn K.F. Endogenous factors in childhood CNSLD. Methodological aspects in populations studies. In “Bronchitis HI”. Royal Vangorcum, Assen, The Netherlands, 1970: p. 38-48.
Lack G., Fox D., Northstone K., Golding J. Factors associated with the development of peanut allergy in childhood. N. Engl. J. Med. 2003; 348(11): 977—985.
Lee C.G., Da Silva C.A., Dela Cruz C.S., Ahangari E, Ma B., Kang M.-J. et al. Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. Annu Rev. Physiol. 2011; 73: 479—501.
Luczynska C.M., Li Y, Chapman M.D., Platts-Mills T.A. Airborne concentrations and particle size distribution of allergen derived from domestic cats (Felis domesticus). Measurements using cascade impactor, liquid impinger, and a two-site monoclonal antibody assay for Fel d I. Am. Rev. Respir. Dis. 1990; 141(2): 361—367.
Mannino D.M., Mott J., Ferdinands J.M., Camargo C.A., Friedman M., Groves H.M. Boys with high body masses have an increased risk of developing asthma: findings from the National Longitudinal Survey of Youth (NLSY). Int. J. Obes. (Lond.) 2006; 30(1): 6-13.
Marsh D.G. Allergens and the genetics of allergy. In: M. Sela (ed.). The Antigens, Academic Press, New York, 1975. Hl: p. 271.
Martorano L., Erwin E.A. Aeroallergen exposure and spread in the modern era. J. Allergy Clin. Immunol. Pract 2018; 6: 1835—1842.
Matricardi P.M., Rosmini E, Ferrigno L., Nisini R., Rapicetta M., Chionne P. et al. Cross sectional retrospective study of prevalence of atopy among Italian military students with antibodies against hepatitis A virus. BMJ 1997; 314(7086): 999—1003.
McWilliams C., Ball S.C., Benjamin S.E., Hales D., Vaughn A., Ward D.S. Best-practice guidelines for physical activity at child care. Pediatrics 2009; 124(6): 1650—1659.
Mitchel E.B., Crow J., Chapman M.D., Jouhal S.S., Pope F.M., Platts-Mills T.A. Basophils in allergen-induced patch test sites in atopic dermatitis. Lancet 1982; 1(8264): 127—130.
Morgan W.J., Crain E.F., Gruchalla R.S., O’Connor G.T., Kattan M., Evans, R. 3rd, et al. Results of a home-based environmental intervention among urban children with asthma. N. Engl. J. Med. 2004; 351(11): 1068-1080.
National Heart, Lung, and Blood Institute. 2007. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. 42. Noon L. Prophylactic innoculation for hay fever. Lancet 1911; i: 1572.
Ownby D.R., Johnson C.C., Peterson E.L. Exposure to dogs and cats in the first year of life and risk of allergic sensitization at 6 to 7 years of age. JAMA 2002; 288(8): 963—972.
Peroni D.G., Piacentini G.L., Costella S., Pietrobelli A., Bodini A., Loiacono A. et al. Mite avoidance can reduce air trapping and airway inflammation in allergic asthmatic children. Clin. Exp. Allergy 2002; 32(6): 850—855.
Perzanowski M.S., Ronmark E., Platts-Mills T.A.E., Lundback B. Effect of cat and dog ownership on sensitization and development of asthma among preteenage children. Am. J. Respir. Crit. Care Med. 2002; 166(5): 696-702.
Perzanowski M.S., Miller R.L., Tang D., Ali D., Garfinkel R.S., Chew G.L. et al. Prenatal acetaminophen exposure and risk of wheeze at age 5 years in an urban low-income cohort. Thorax 2010; 65(2): 118-123.
Platts-Mills T., Mitchell E., Tovey E., Chapman M., Wilkins S. Airborne allergen exposure, allergen avoidance and bronchial hyperreactivity, pp. 297—314. In: Kay A.B., Austen K.F., Lichtenstein LM (eds.). Asthma: Physiology, Immunopharmacology and Treatment. Third International Symposium. London: Academic Press, 1984.
Platts-Mills T.A., Vervloet D., Thomas W.R., Aslberse R.C., Chapman M.D. Indoor allergens and asthma: report of the Third International Workshop. J. Allergy Clin. Immunol. 1997a; 100(6 Pt I): S2-24.
Platts-Mills T.A., Sporik R.B., Chapman M.D., Heymann P.W. The role of domestic allergens. The rising trends in Asthma, 1997. Ciba Foundation Symp. 1997b: pp. 173—189.
Platts-Mills T., Vaughan J., Squillace S., Woodfolk J., Sporik R. Sensitisation, asthma, and a modified Th2 response in children exposed to cat allergen: a population-based cross-sectional study. Lancet 2001; 357(9258): 752—756.
Platts-Mills T.A.E., Perzanowski M., Woodfolk J.A., Lundback B. Relevance of early or current pet ownership to the prevalence of allergic disease. Clin. Exp. Allergy 2002; 32(3): 335-338.
Platts-Mills T.A. Allergen avoidance in the treatment of asthma: problems with the metaanalyses. J. Allergy Clin. Immunol. 2008; 122(4): 694—696.
Platts-Mills T.A.E. Indoor Allergens, pp. 453—469. In: Adkinson N., Bochner B., Burks A., Busse W., Holgate S., Lemanske R., O’HehirR. (eds.). Middleton’s Allergy: Principlesand Practice: 8th edition. Elsevier, 2013.
Salter H.H. Asthma: Its Pathology and Treatment. William Wood, New York, 1882.
Savage J.H., Matsui E.C., Wood R.A., Keet C.A. Urinary levels of triclosan and parabens are associated with aeroallergen and food sensitization. J. Allergy Clin. Immunol. 2012; 130(2): 453-60 e7.
Schuyler A.J., Wilson J.M., Tripathi A., Commins S.P., Ogbogu P.U., Kruzsewski P.G., et al. Specific IgG4 antibodies to cow’s milk proteins in pediatric patients with eosinophilic esophagitis. J. Allergy Clin. Immunol. 2018 Jul; 142(1): 139—148.
Shim Y.M., Burnette A., Lucas S., Herring R.C., Weltman J., Patrie J.T. et al. Physical deconditioning as a cause of breathlessness among obese adolescents with a diagnosis of asthma. 2012 submitted.
Shirakawa T., Enomoto T., Shimazu S., Hopkin J.M. The inverse association between tuberculin responses and atopic disorder. Science 1997; 3(275): 77—79.
Simpson A., Custovic A. Allergen avoidance in the primary prevention of asthma. CurrO-pin Allergy Clin. Immunol 2004; 4(1): 45—51.
Skloot G., Permutt S., Togias A. Airway hyperresponsiveness in asthma: a problem of limited smooth muscle relaxation with inspiration. J. Clin. Invest 1995; 96(5): 2393—2403.
Smith J., Disney M.E., Willaims J.D., Goels Z.A. Clinical significance of skin reactions to mite extracts in children with asthma. Br. Med. J. 1969; 2(5659): 723—726.
Smith R., Lourie B. Slow Death by Rubber Duck: The Secret Danger of Everyday Things. Counterpoint, Berkeley, CA, USA 2011.
Sporik R., Ingram J.M., Price W., Sussman J.H., Honsinger R.W., Platts-Mils T.A. Association of asthma with serum IgE and skin test reactivity to allergens among children living at high altitude. Tickling the dragon’s breath. Am. J. Respir. Crit. Care Med. 1995; 151(5): 1388-1392.
Taliafero T.A. Skin reactions in Schistosomiasis. Puerto Rico J. Publ. Health 1931; 7(23).
Tovey E.R., Chapman M.D., Platts-Mills T.A. Mite faeces are a major source of house dust allergens. Nature 1981a; 289(5798): 592-593.
Tovey E.R., Chapman M.D., Wells C.W., Platts-MillsT.A. The distribution of dust mite allergen in the houses of patients with asthma. Am. Rev. Respir. Dis. 1981b; 124(5): 630—635.
Trompette A., Divanovic S., Visintin A., Blanchard C., Hegde, Madan R., et al. Allergenicity resulting from functional mimicry of a Toll-like receptor complex protein. Nature 2009; 457(7229): 585-588.
Voorhorst R., Spieksma F.Th.M., Varekamp H., Leupen MJ., Lyklema A.W. The house dust mite (Dermatophagoides pteronyssinus) and the allergens it produces. Identify with the house dust allergen. J. Allergy 1967;39: 325.
Walzer M., Siegel B.B. The effectiveness of the ragweed eradication campaigns in New York City; a 9-year study; 1946—1954. J. Allergy 1956; 27(2): 113—126.
Weiss K.B., Gergen P.J., Wagener D.K. Breathing better or wheezing worse? The changing epidemiology of asthma morbidity and mortality. Annu. Rev. Public Health 1993; 14: 491-513.
Wood R.A., Chapman M.D., Adkinson N.F., Jr, Eggleston P.A. The effect of cat removal on allergen content in household-dust samples. J. Allergy Clin. Immunol. 1989; 83(4): 730-734.
Wood R.A., Johnson E.F., Van Natta M.L., Chen P.H., Eggleston P.A. A placebo-con-trolled trial of a HEPA air cleaner in the treatment of cat allergy. Am. J. Respir. Crit. Care Med. 1998; 1998(158): 1.
Woolcock A.J., Peat J.K. Evidence forthe increase in asthma worldwide. Ciba Found Symp 1997; 206: 157-159.
Zeiger R.S. Food allergen avoidance in the prevention of food allergy in infants and children. Pediatrics 2003; 111(6): 1662-1671.
Chinthrajah R.S., Hernandez J.D., Boyd S.D., et?al. Molecular and cellular mechanisms of food allergy and food tolerance. J Allergy Clin Immunol. 2016;137:984?997.
Sampath V., Tupa D., Graham M.T., et?al. Deciphering the black box of food allergy mechanisms. Ann Allergy Asthma Immunol. 2017;118:21?27.
Muraro A., Lemanske R.F. Jr, Castells M., et?al. Precision medicine in allergic disease-food allergy, drug allergy, and anaphylaxis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology. Allergy. 2017;72:1006?1021.
Lyons S.A., Burney P.G.J., Ballmer-Weber B.K., et?al. Food allergy in adults: substantial variation in prevalence and causative foods across Europe. J Allergy Clin Immunol Pract. 2019. [Epub ahead of print.]
Jalbert I., Golebiowski B. Environmental aeroallergens and allergic rhino-conjunctivitis. Curr Opin Allergy Clin Immunol. 2015;15:476?481.
Schaefer P. Acute and chronic urticaria: evaluation and treatment. Am Fam Physician. 2017;95:717?724.
Berghi N.O. Immunological mechanisms implicated in the pathogenesis of chronic urticaria and Hashimoto thyroiditis. Iran J Allergy Asthma Immunol. 2017;16:358?366.
Han H., Roan F., Ziegler S.F. The atopic march: current insights into skin barrier dysfunction and epithelial cell-derived cytokines. Immunol Rev. 2017;278:116?130.
Wheatley L.M., Togias A. Clinical practice. Allergic rhinitis. N Engl J Med. 2015;372:456?463.
Samitas K., Delimpoura V., Zervas E., et?al. Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives. Eur Respir Rev. 2015;24:594?601.
Wen T., Rothenberg M.E. Clinical applications of the eosinophilic esophagitis diagnostic panel. Front Med (Lausanne). 2017;4:108-114.
Gonsalves N. Eosinophilic gastrointestinal disorders. Clin Rev Allergy Immunol. 2019. [Epub ahead of print.]
LoVerde D., Iweala O.I., Eginli A., et?al. Anaphylaxis. Chest. 2018;153:528?543.
Kaplan A.P., Joseph K. Pathogenesis of hereditary angioedema: the role of the bradykinin-forming cascade. Immunol Allergy Clin North Am. 2017;37:513?525.
Tourlas K., Burman D. Allergy testing. Prim Care. 2016;43:363?374.
Picard C., Al-Herz W., Bousfiha A., et?al. Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015. J Clin Immunol. 2015;35:696?726.
Picard C, Gaspar H.B., Al-Herz W, et?al. International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity. J Clin Immunol. 2018;38:96?128.
Seidel M.G., Kindle G., Gathmann B., et?al. The European Society for Immunodeficiencies (ESID) Registry working definitions for the clinical diagnosis of inborn errors of immunity. J Allergy Clin Immunol Pract. 2019. [Epub ahead of print.]
Mahlaoui N., Warnatz K., Jones A., et?al. Advances in the care of primary immunodeficiencies (PIDs): from birth to adulthood. J Clin Immunol. 2017;37:452?460.
Bousfiha A., Jeddane L., Al-Herz W., et?al. The 2015 IUIS phenotypic classification for primary immunodeficiencies. J Clin Immunol. 2015;35:727?738.
Dorsey M.J., Dvorak C.C., Cowan M.J., et?al. Treatment of infants identified as having severe combined immunodeficiency by means of newborn screening. J Allergy Clin Immunol. 2017;139: 733?742.
Fox T.A., Chakraverty R., Burns S., et?al. Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency. Blood. 2018;131:917?931.
Thrasher A.J., Williams D.A. Evolving gene therapy in primary immunodeficiency. Mol Ther. 2017;25:1132?1141.
Kohn D.B., Kuo C.Y. New frontiers in the therapy of primary immunodeficiency: from gene addition to gene editing. J Allergy Clin Immunol. 2017;139:726?732.
Dimitrova D., Freeman A.F. Current status of dedicator of cytokinesis-associated immunodeficiency: DOCK8 and DOCK2. Dermatol Clin. 2017;35:11?19.
Gerrits A.J., Leven E.A., Freling?er A.L. 3rd, et?al. Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia. Blood. 2015;126:1367?1378.
van Os N.J.H., Haaxma C.A., van der Flier M., et?al. Ataxia-telangiectasia: recommendations for multidisciplinary treatment. Dev Med Child Neurol. 2017;59:680?689.
Morsheimer M., Brown Whitehorn T.F., Heimall J., et?al. The immune deficiency of chromosome 22q11.2 deletion syndrome. Am J Med Genet A. 2017;173:2366?2372.
Davies E.G., Cheung M., Gilmour K., et?al. Thymus transplantation for complete DiGeorge syndrome: European experience. J Allergy Clin Immunol. 2017;140:1660?1670.
Kostjukovits S., Klemetti P., Valta H., et?al. Analysis of clinical and immunologic phenotype in a large cohort of children and adults with cartilage-hair hypoplasia. J Allergy Clin Immunol. 2017;140: 612?614.
Bonilla F.A., Barlan I., Chapel H., et?al. International Consensus Document (ICON): common variable immunodeficiency disorders. J Allergy Clin Immunol Pract. 2016;4:38?59.
Maffucci P., Filion C.A., Boisson B., et?al. Genetic diagnosis using whole exome sequencing in Common Variable Immunodeficiency. Front Immunol. 2016;7:1?9.
Yazdani R., Fekrvand S., Shahkarami S., et?al. The hyper IgM syndromes: epidemiology, pathogenesis, clinical manifestations, diagnosis and management. Clin Immunol. 2019;198:19?30.
Yazdani R., Azizi G., Abolhassani H., et?al. Selective IgA deficiency: epidemiology, pathogenesis, clinical phenotype, diagnosis, prognosis and management. Scand J Immunol. 2017;85: 3?12.
Perez E., Bonilla F.A., Orange J.S., Ballow M. Specific antibody deficiency: controversies in diagnosis and management. Front Immunol. 2017;8:1?11.
Tangye S.G., Palendira U., Edwards E.S. Human immunity against EBV-lessons from the clinic. J Exp Med. 2017;214:269?283.
Rieux-Laucat F., Magerus-Chatinet A., Neven B. The autoimmune lymphoproliferative syndrome with defective FAS or FAS-ligand functions. J Clin Immunol. 2018;38:558?568.
Bacchetta R., Barzaghi F., Roncarolo M.G. From IPEX syndrome to FOXP3 mutation: a lesson on immune dysregulation. Ann N Y Acad Sci. 2018;1417:5?22.
Gonzalez-Lara M.F., Wisniowski-Yanez A., Perez-Patrigeon S., et?al. Pneumocystis jiroveci pneumonia and GATA2 deficiency: expanding the spectrum of the disease. J Infect. 2017;74:425?427.
Sharma M., Bennett C., Carter B., et?al. H1-antihistamines for chronic spontaneous urticaria: an abridged Cochrane Systematic review. J Am Acad Dermatol. 2015;73:710?716.
Guill?n-Aguinaga S., J?uregui Presa I., Aguinaga-Ontoso E., et?al. Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis. Br J Dermatol. 2016;175:1153?1165.
Fedorowicz Z., van Zuren E.J., Hu N. Histamine H2-receptor antagonists for urticaria. Cochrane Database Syst Rev. 2012;3:CD008596.
Maurer M., Rosen K., Hsieh H.J., et?al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368:924?935.
Dressler C., Werner R.N., Eisert L., et?al. Chronic inducible urticaria: a systematic review of treatment options. J Allergy Clin Immunol. 2018;141:1726?1734.
Riedl M.A., Bernstein J.A., Li H., et?al. Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial. Ann Allergy Asthma Immunol. 2014;112:163?169.
Cicardi M., Banerji A., Bracho F., et?al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med. 2010;363:532?541.
Lumry W.R., Li H.H., Levy R.J., et?al. Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol. 2011;107:529?537.
Cicardi M., Levy R.J., McNeil D.L., et?al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med. 2010;363:523?531.
Lewis L.M., Graffeo C., Crosley P., et?al. Ecallantide for the acute treatment of angiotensin-converting enzyme inhibitor-induced angioedema: a multicenter, randomized, controlled trial. Ann Emerg Med. 2014;65:204?213.
Zuraw B.L., Busse P.J., White M., et?al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med. 2010;363:513?522.
Riedl M.A., Grivcheva-Panovska V., Moldovan D., et?al. Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial. Lancet. 2017;390:1595?1602.
Banerji A., Busse P., Shennak M., et?al. Inhibiting plasma kallikrein for hereditary angioedema prophylaxis. N Engl J Med. 2017;376:717?728.
Aygoren-P?rs?n E., Bygum A., Grivcheva-Panovska V., et?al. Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema. N Engl J Med. 2018;379:352?362.
Longhurst H., Cicardi M., Craig T., et?al. Prevention of hereditary angioedema attacks with a sub-cutaneous C1 inhibitor. N Engl J Med. 2017;376:1131?1140.
Bao M., Greve J., Stelter K., et?al. A randomized trial of icatibant in ACE-inhibitor-induced angioedema. N. Engl J Med. 2015;372:418?425.
LoVerde D., Files D.C., Krishnaswamy G. Angioedema. Crit Care Med. 2017;45:725?735.
Maurer M., Vena G.A., Cassano N., et?al. Current and future therapies for treating chronic spontaneous urticaria. Expert Opin Pharmacother. 2016;17:1131?1139.
Zuberbier T, Aberer W, Asero R, et?al. The EAACI/GA(2)LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73:1393?1414.
Shahzad Mustafa S., S?nchez-Borges M. Chronic urticarial: comparisons of US, European, and Asian guidelines. Curr Allergy Asthma Rep. 2018;18:1?7.
Beck L.A., Bernstein J.A., Maurer M. A review of international recommendations for the diagnosis and management of chronic urticaria. Acta Derm Venereol. 2017;97:149?158.
Davis M.D.P., van der Hilst J.C.H. Mimickers of urticarial: urticarial vasculitis and autoinflammatory diseases. J Allergy Clin Immunol Pract. 2018;6:1162?1170.
Maurer M., Fluhr J.W., Khan D.A. How to approach chronic inducible urticaria. J Allergy Clin Immunol Pract. 2018;6:1119?1130.
Curto-Barredo L., Gimenez-Arnau A.M. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamine. G Ital Dermatol Venereol. 2019. [Epub ahead of print.]
Ugert M.C., van den Elzen M.T., Knulst A.C., et?al. Omalizumab in patients with chronic spontaneous urticaria: a systematic review and GRADE assessment. Br J Dermatol. 2015;173:404?415.
Zeerleder S., Levi M. Hereditary and acquired C1-inhibitor-dependent angioedema: from pathophysiology to treatment. Ann Med. 2016;48:256?267.
Kostis W.J., Shetty M., Chowdhury Y.S., et?al. ACE inhibitor-induced angioedema: a review. Curr Hypertens Rep. 2018;20:55.
De Maat S., Hofman Z.L.M., Maas C. Hereditary angioedema: the plasma contact system out of control. J Thromb Haemost. 2018;16:2349?2351.
Bova M., De Feo G., Parente R., et?al. Hereditary and acquired angioedema: heterogeneity of pathogenesis and clinical phenotypes. Int Arch Allergy Immunol. 2018;175:126?135.
Zuraw B.L., Christiansen S.C. How we manage persons with hereditary angioedema. Br J Haematol. 2016;173:831?843.
Bork K. A decade of change: recent developments in pharmacotherapy of hereditary angioedema (HAE). Clini Rev Allergy Immunol. 2016;51:183?192.
Grunau B.E., Wiens M.O., Rowe B.H., et?al. Emergency department corticosteroid use for allergy or anaphylaxis is not associated with decreased relapses. Ann Emerg Med. 2015;66:381?389.
Vickery B.P., Vereda A., Casale T.B., et?al. AR101 Oral immunotherapy for peanut allergy. N Engl J Med. 2018;379:1991?2001.
Wang J., Sampson H.A. Safety and efficacy of epicutaneous immunotherapy for food allergy. Pediatr Allergy Immunol. 2018;29:341?349.
Boyle R.J., Elremeli M., Hockenhull J., et?al. Venom immunotherapy for preventing allergic reactions to insect stings. Cochrane Database Syst Rev. 2012;10:CD008838.
Du Toit G., Sayre P.H., Roberts G., et?al. Effect of avoidance on peanut allergy after early peanut consumption. N Engl J Med. 2016;374:1435?1443.
Altman A.M., Camargo C.A. Jr, Simons F.E., et?al. Anaphylaxis in America: a national physician survey. J Allergy Clin Immunol. 2015;135:830-833.
Hsu Blatman K.S., Hepner D.L. Current knowledge and management of hypersensitivity to perioperative drugs and radiocontrast media. J Allergy Clin Immunol Pract. 2017;5:587?592.
Worm M., Francuzik W., Renaudin J.M., et?al. Factors increasing the risk for a sever reaction in anaphylaxis: an analysis of data from the European Anaphylaxis Registry. Allergy. 2018. [Epub ahead of print.]
Gupta R.S., Warren C.M., Smith B.M., et?al. Prevalence and severity of food allergies among US adults. JAMA Netw Open. 2019;2:1?14.
Wu M., McIntosh J., Liu J. Current prevalence rate of latex allergy: why it remains a problem? J Occup Health. 2016;58:138?144.
Jones S.M., Burks A.W. Food allergy. N Engl J Med. 2017;377:1168?1176.
Feldweg A.M. Food-dependent, exercise-induced anaphylaxis: diagnosis and management in the outpatient setting. J Allergy Clin Immunol Pract. 2017;5:283?288.
McNeil M.M., Weintraub E.S., Duffy J., et?al. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol. 2016;137:868?878.
Boyden S.E., Desai A., Cruse G., et?al. Vibratory urticaria associated with a missense variant in ADGRE2. N Engl J Med. 2016;374:656?663.
Gaudinski M.R., Milner J.D. Atopic dermatitis and allergic urticaria: cutaneous manifestations of immunodeficiency. Immunol Allergy Clin North Am. 2017;37:1?10.
Bonadonna P., Bonifacio M., Lombardo C., Zanotti R. Hymenoptera allergy and mast cell activation syndromes. Curr Allergy Asthma Rep. 2016;16:1?9.
Lyons J.J. Hereditary alpha tryptasemia: genotyping and associated clinical features. Immunol Allergy Clin North Am. 2018;38:483-495.
Sabato V., Chovanec J., Faber M., et?al. First identification of an inherited TPSAB1 quintuplication in a patient with clonal mast cell disease. J Clin Immunol. 2018;38:457?459.
Gillis C.M., Jonsson F., Mancardi D.A., et?al. Mechanisms of anaphylaxis in human low-affinity IgG receptor locus knock-in mice. J Allergy Clin Immunol. 2017;139:1253?1265.
Mukai K., Tsai M., Starkl P., et?al. IgE and mast cells in host defense against parasites and venoms. Semin Immunopathol. 2016;38:581?603.
Lotfi-Emran S., Ward B.R., Le Q.T., et?al. Human mast cells present antigen to autologous CD4+ T Cells. J Allergy Clin Immunol. 2018;141:311?321.
Lieberman P., et?al. Anaphylaxis — a practice parameter update 2015. Ann Allergy Asthma Immunol. 2015;115:341?384.
Valent P., Akin C., Hartmann K., et?al. Advances in the classification and treatment of mastocytosis: current status and outlook toward the future. Cancer Res. 2017;77:1261?1270.
Seth S., Khan D.A. The comparative safety of multiple alternative agents in refractory chronic urticaria patients. J Allergy Clin Immunol Pract. 2017;5:165?170.
Dosa I., Caubet J.C., Brockow K., et?al. An EAACI task force report: recognizing the potential of the primary care physician in the diagnosis and management of drug hypersensitivity. Clin Transl Allergy. 2018;8:1?12.
Tacquard C., Collane O., Gomis P., et?al. Anaesthetic hypersensitivity reactions in France between 2001 and 2012: the 10th GERAP epidemiologic survey. Acta Anaesthesiol Scand. 2017;61: 290?299.
Pichler W.J., Srinoulprasert Y., Yun J., et?al. Multiple drug hypersensitivity. Int Arch Allergy Immunol. 2017;172:129?138.
Shenoy E.S., Macy E., Rowe T., et?al. Evaluation and management of penicillin allergy: a review. JAMA. 2019;321:188?199.
Jones B.M., Bland C.M. Penicillin skin testing as an antimicrobial stewardship initiative. Am J Health Syst Pharm. 2017;74:232?237.
Garon S.L., Pavlos R.K., White K.D., et?al. Pharmacogenomics of off-target adverse drug reactions. Br J Pharmacol. 2017;83:1896?1911.
Blakely K.M., Drucker A.M., Rosen C.F. Drug-induced photosensitivity-an update: culprit drugs, pre-vention and management. Drug Saf. 2019. [Epub ahead of print.]
Duong T.A., Valeyrie-Allanore L., Wolkenstein P., et?al. Severe cutaneous adverse reactions to drugs. Lancet. 2017;390:1996?2011.
Alvarado S.A., Mu?oz-Mendoza D., Bahna S.L. High-risk drug rashes. Ann Allergy Asthma Immunol. 2018;121:552?560.
Lerch M., Mainetti C., Terzioli Beretta-Piccoli B., et?al. Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis. Clin Rev Allergy Immunol. 2018;54:147?176.
Musette P., Janela B. New insights into drug reaction with eosinophilia and systemic symptoms pathophysiology. Front Med (Lausanne). 2017;4:1?7.
Mustafa S.S., Ostrov D., Yerly D. Severe cutaneous adverse drug reactions: presentation, risk factors, and management. Curr Allergy Asthma Rep. 2018;18:1?9.
Wickner P.G., Hong D. Immediate drug hypersensitivity. Curr Allergy Asthma Rep. 2016;16:49.
Macy E., Romano A., Khan D. Practical management of antibiotic hypersensitivity in 2017. J Allergy Clin Immunol Pract. 2017;5:577?586.
Pardanani A. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and man-agement. Am J Hematol. 2019;94:363?377.
Gotlib J., Gerds A.T., Bose P., et?al. Systemic mastocytosis, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16:1500?1537.
Valent P., Akin C., Hartmann K., et?al. Advances in the classification and treatment of mastocytosis: current status and outlook toward the future. Cancer Res. 2017;77:1261?1270.
Scherber R.M., Borate U. How we diagnose and treat systemic mastocytosis in adults. Br J Haematol. 2018;180:11?23.
Theoharides T.C., Valent P., Akin C. Mast cells, mastocytosis, and related disorders. N Engl J Med. 2015;373:163?172.
Fletcher L., Borate U. Novel approaches for systemic mastocytosis. Curr Opin Hematol. 2019;26: 112?118.
Gotlib J., Kluin-Nelemans H.C., George T.I., et?al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med. 2016;374:2530?2541.
Barete S., Lortholary O., Damaj G., et?al. Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis. Blood. 2015;126:1009?1016.
Garcia-Montero A.C., Jara-Acevedo M., Alvarez-Twose I., et?al. KIT D816V-mutated bone marrow mesenchymal stem cells in indolent systemic mastocytosis are associated with disease progression. Blood. 2016;127:761?768.
Труды отечественных авторов при подготовке статей по терапии для пользователей сайта - не использовались, так как их вы всегда можете найти в библиотеках.
